Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/38813
Title: Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy
Authors: Valgimigli, Marco
Frigoli, Enrico
VRANCKX, Pascal 
Ozaki, Yukio
Morice, Marie-Claude
Chevalier, Bernard
Onuma, Yoshinobu
Windecker, Stephan
Delorme, Laurent
Kala, Petr
Kedev, Sasko
Abhaichand, Rajpal K.
Velchev, Vasil
Dewilde, Willem
Podolec, Jakub
Leibundgut, Gregor
Topic, Dragan
Schultz, Carl
Stankovic, Goran
Lee, Astin
Johnson, Thomas
Tonino, Pim A. L.
Klotzka, Aneta
Lesiak, Maciej
Lopes, Renato D.
Smits, Pieter C.
Heg, Dik
Issue Date: 2022
Publisher: ELSEVIER SCIENCE INC
Source: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 80 (8) , p. 766 -778
Abstract: BACKGROUND Nonadherence to antiplatelet therapy after percutaneous coronary intervention (PCI) is common, even in clinical trials. OBJECTIVES The purpose of this study was to investigate the impact of nonadherence to study protocol regimens in the MASTER DAPT (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen) trial. METHODS At 1-month after PCI, 4,579 high bleeding risk patients were randomized to single antiplatelet therapy (SAPT) for 11 months (or 5 months in patients on oral anticoagulation [OAC]) or dual antiplatelet therapy (DAPT) for >= 2 months followed by SAPT. Coprimary outcomes included net adverse clinical events (NACE), major adverse cardiac and cerebral events (MACE), and major or clinically relevant nonmajor bleeding (MCB) at 335 days. Inverse probability-ofcensoring weights were used to correct for nonadherence Academic Research Consortium type 2 or 3. RESULTS In total, 464 (20.2%) patients in the abbreviated-treatment and 214 (9.4%) in the standard-treatment groups incurred nonadherence Academic Research Consortium type 2 or 3. At inverse probability-of-censoring weights analyses, NACE (HR: 1.01; 95% CI: 0.88-1.27) or MACE (HR: 1.07; 95% CI: 0.83-1.40) did not differ, and MCB was lower with abbreviated compared with standard treatment (HR: 0.51; 95% CI: 0.60-0.73) consistently across OAC subgroups; among OAC patients, SAPT discontinuation 6 months after PCI was associated with similar MACE and lower MCB (HR: 0.47; 95% CI: 0.22-0.99) compared with SAPT continuation. CONCLUSIONS In the MASTER DAPT adherent population, 1-month compared with >= 3-month DAPT was associated with similar NACE or MACE and lower MCB. Among OAC patients, SAPT discontinuation after 6 months was associated with similar MACE and lower MCB than SAPT continuation (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; (C) 2022 by the American College of Cardiology Foundation.
Notes: Valgimigli, M (corresponding author), Univ Svizzera Italiana USI, Cardioctr Inst, Ente Osped Cantonale, CH-6900 Lugano, Switzerland.
marco.valgimigli@eoc.ch
Keywords: drug-eluting stent;dual antiplatelet therapy;high bleeding risk;P2Y12 inhibitor;acetylsalicylic acid
Document URI: http://hdl.handle.net/1942/38813
ISSN: 0735-1097
e-ISSN: 1558-3597
DOI: 10.1016/j.jacc.2022.04.065
ISI #: 000863530300004
Rights: 2022 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER
Category: A1
Type: Journal Contribution
Validations: ecoom 2023
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy.pdfPublished version872.68 kBAdobe PDFView/Open
Show full item record

WEB OF SCIENCETM
Citations

6
checked on May 8, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.